1. Editor’s Commentary

   • J. Rick Turner

   Commentary 30 December 2012 Pages: 643 - 644

2. Associate Editor’s Commentary: In Praise of a BRAT

   • Peter J. Pitts

   Commentary 30 December 2012 Pages: 645 - 646

3. A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials

   • Brian A. Millen
   • Alex Dmitrienko
   • Lei Shen

   Statistics 30 December 2012 Pages: 647 - 656

4. Clinical Trials: Rethinking How We Ensure Quality

   • Martin J. Landray
   • Cheryl Grandinetti
   • Rachel E. Sherman

   Clinical Trials 30 December 2012 Pages: 657 - 660

5. The Effect of Feedback With Photo-Novella Information Sheets on Subjects’ Understanding in Informed Consent for Research

   • Ihn Sook Jeong
   • Jang Hee Hong
   • Jae Sim Jeong

   Clinical Trials 30 December 2012 Pages: 661 - 668

6. Interventions Assessment of Prescription Automatic Screening System in Chinese Hospitals: A Systematic Review

   • Chunyan Yang
   • Lianping Yang
   • Xinping Zhang

   Drug Information 30 December 2012 Pages: 669 - 676

7. Use of Proprietary Names by Prescribers for Discontinued Brand Drug Products With Existing Generic Equivalents

   • Chi-Ming Tu
   • Kellie Taylor
   • Grace Chai

   Drug Information 30 December 2012 Pages: 677 - 682

8. The Future of Allergen-Specific Immunotherapy

   • Marek Jutel
   • Katarzyna Solarewicz-Madejek
   • Sylwia Smolińska

   Drug Information 30 December 2012 Pages: 683 - 687

9. Dispensed Medications: Labeling Patterns and Patient Knowledge at a Tertiary Care University Hospital in Southwest Ethiopia

   • Hawi Yabite
   • Shibiru Tessema
   • Nasir Tajure Wabe

   Drug Information 30 December 2012 Pages: 688 - 693

10. Are Pharmaceutical Market Withdrawals Preventable? A Preliminary Analysis

    • Jaya Sai V. Daggumalli
    • Irwin G. Martin

    Drug Safety 30 December 2012 Pages: 694 - 700

11. Heat Map Displays for Data From Human Abuse Potential Crossover Studies

    • Ling Chen
    • Yang Wang

    Drug Safety 30 December 2012 Pages: 701 - 707

12. Adverse Reaction Signaling and Disproportionality Analysis: An Update

    • Gerald Faich
    • Jonathan Morris

    Drug Safety 30 December 2012 Pages: 708 - 714

13. Content Analysis of the Videos Featuring Prescription Drug Advertisements in Social Media: YouTube

    • Mo Yang
    • Jeongeun Seo
    • Sujit S. Sansgiry

    Communications 30 December 2012 Pages: 715 - 722

14. Evaluating the Content of Advertisements for Dietary Supplements in Malaysian Women’s Magazines

    • Mohamed Azmi Hassali
    • Fahad Saleem
    • Tahir Mehmood Khan

    Communications 30 December 2012 Pages: 723 - 728

15. Development of a Web-Based Compliance Metrics Reporting Dashboard (CMR^©) for Medical Information Inquiries

    • Robert J. Fuentes
    • Kazeem Idowu
    • Sanjay K. Sahoo

    Communications 30 December 2012 Pages: 729 - 735

16. Application of the Benefit-Risk Action Team (BRAT) Framework in Pharmaceutical R&D: Results From a Pilot Program

    • Rebecca Noel
    • Richard Hermann
    • Kristin Van Goor

    Benefit-Risk Assessment 30 December 2012 Pages: 736 - 743

17. Review of From Alzheimer’s to Zebrafish: Eclectic Science and Regulatory Stories

    • Edward Tabor

    Book Reviews 30 December 2012 Pages: 744 - 744

18. Review of Good Clinical Practice: A Question & Answer Reference Guide

    • Edward Tabor

    Book Reviews 30 December 2012 Pages: 744 - 745

19. Review of Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional

    • Edward Tabor

    Book Reviews 30 December 2012 Pages: 745 - 746

20. Review of IND Submissions: A Primer

    • Edward Tabor

    Book Reviews 30 December 2012 Pages: 746 - 746

21. Review of Clinical Trial Design: Bayesian and Frequentist Adaptive Methods

    • Richard C. Zink

    Book Reviews 30 December 2012 Pages: 746 - 747

22. DIA/NORD 2012 US Conference on Rare Diseases and Orphan Products: Poster Abstracts

    Abstracts 30 December 2012 Pages: 748 - 758